Muscle mass predicts outcomes following liver transplantation

Andrea DiMartini, Ruy J. Cruz, Mary Amanda Dew, Larissa Myaskovsky, Bret Goodpaster, Kristen Fox, Kevin H. Kim, Paulo Fontes – 20 August 2013 – For patients with end‐stage liver disease, commonly used indices of nutritional status (ie, body weight and body mass index) are often inflated because of fluid overload (ie, ascites and peripheral edema), and this results in an underdiagnosis of malnutrition. Because muscle is the largest protein reservoir in the body, an estimate of the muscle mass may be a more reliable and valid estimate of nutritional status.

Three‐dimensional print of a liver for preoperative planning in living donor liver transplantation

Nizar N. Zein, Ibrahim A. Hanouneh, Paul D. Bishop, Maggie Samaan, Bijan Eghtesad, Cristiano Quintini, Charles Miller, Lisa Yerian, Ryan Klatte – 20 August 2013 – The growing demand for liver transplantation and the concomitant scarcity of cadaveric livers have increased the need for living donor liver transplantation (LDLT). Ensuring the safety of donors and recipients is critical.

Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

Samuele Minicis, Chiara Rychlicki, Laura Agostinelli, Stefania Saccomanno, Cinzia Candelaresi, Luciano Trozzi, Eleonora Mingarelli, Bruna Facinelli, Gloria Magi, Claudio Palmieri, Marco Marzioni, Antonio Benedetti, Gianluca Svegliati‐Baroni – 19 August 2013 – Nonalcoholic fatty liver disease (NAFLD) may lead to hepatic fibrosis. Dietary habits affect gut microbiota composition, whereas endotoxins produced by Gram‐negative bacteria stimulate hepatic fibrogenesis. However, the mechanisms of action and the potential effect of microbiota in the liver are still unknown.

Human CD14+CTLA‐4+ regulatory dendritic cells suppress T‐cell response by cytotoxic T‐lymphocyte antigen‐4‐dependent IL‐10 and indoleamine‐2,3‐dioxygenase production in hepatocellular carcinoma

Yanmei Han, Zhubo Chen, Yuan Yang, Zhengping Jiang, Yan Gu, Yangfang Liu, Chuan Lin, Zeya Pan, Yizhi Yu, Minghong Jiang, Weiping Zhou, Xuetao Cao – 19 August 2013 – Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited therapeutic options. HCC‐induced immunosuppression often leads to ineffectiveness of immuno‐promoting therapies. Currently, suppressing the suppressors has become the potential strategy for cancer immunotherapy.

Subscribe to